✦ LIBER ✦

A phase II study of DaunoXome® in advanced urothelial transitional cell carcinoma

✍ Scribed by S.D. Fosså; N. Aass; G. Parö

Book ID: 117664218
Publisher: Elsevier Science
Year: 1998
Tongue: English
Weight: 44 KB
Volume: 34
Category: Article
ISSN: 0959-8049
DOI: 10.1016/s0959-8049(97)10156-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II study of 4-epi-adriamycin in

A phase II study of 4-epi-adriamycin in advanced urothelial transitional cell cancer

✍ Fosså, Sophie D.; Splinter, Ted; Roozendaal, Klaas J.; Veenhof, Kees H.N.; Pavon 📂 Article 📅 1989 🏛 Elsevier Science ⚖ 186 KB

A phase II study of gemcitabine and oxal

A phase II study of gemcitabine and oxaliplatin in advanced transitional cell carcinoma of the bladder

✍ Zeynep Eroglu, John P. Fruehauf 📂 Article 📅 2013 🏛 Springer 🌐 English ⚖ 211 KB

1152 Gemcitabine in the treatment of pat

1152 Gemcitabine in the treatment of patients with advanced transitional cell carcinoma: A phase II study

✍ Kuzel, T.; Stadler, W.; Raghavan, D.; Levine, E.; Vogelzang, N.; Roth, B.; Dorr, 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 160 KB

A phase II trial of R115777, an oral far

A phase II trial of R115777, an oral farnesyl transferase inhibitor, in patients with advanced urothelial tract transitional cell carcinoma

✍ Jonathan E. Rosenberg; Hans von der Maase; John D. Seigne; Jozef Mardiak; David 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 100 KB 👁 1 views

A phase II study of mitoguazone and vinb

A phase II study of mitoguazone and vinblastine in advanced transitional cell carcinoma of the urinary tract

✍ John T. Barrett; Bruno Orofiamma; Janardan D. Khandekar; Paul P. Carbone; Robert 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 330 KB 👁 2 views

This is a comparative study to evaluate response rate to mitoguazone (MGBG) and vinblastine (VLB) in 52 evaluable patients with advanced transitional cell carcinoma of the urinary tract. Of 38 patients with measurable disease, two of 18 (11%) on MGBG had partial remission (95% confidence interval: 0

Phase II study of VP 16-213 (etoposide)

Phase II study of VP 16-213 (etoposide) in metastatic transitional cell urothelial cancer

✍ B. A. J. Ponder; R. T. D. Oliver 📂 Article 📅 1984 🏛 Springer 🌐 English ⚖ 227 KB